An unnamed drug maker has applied for U.S. regulatory approval to sell a generic version of Allergan Inc.’s eyelash-enhancing drug Latisse before its patent protection expires.

Latisse, approved in late 2008 with $73.3 million in sales last year, has market exclusivity until late 2011. But the  Food and Drug Administration disclosed last week that a company filed an application in May to market a copycat version by challenging Allergan’s patent for the drug. The FDA didn’t identify the applicant of the generic drug. Get the full story »